ARFGEF2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from HT29 cells, featuring disruption of the ARFGEF2 gene. This heterogeneous knockout model enables study of gene function without clonal selection, reflecting native cellular variability and providing a more physiologically relevant system for population-level analyses. The cells serve as a tool for investigating ARFGEF2-dependent processes, particularly in the context of colorectal adenocarcinoma.
HT29 is a human colorectal adenocarcinoma epithelial cell line established from a 44-year-old female patient. Widely used in cancer research, these cells form polarized monolayers, modeling intestinal epithelial biology and expressing relevant differentiation markers. They are employed in studies of colon carcinoma, drug metabolism, and chemoresistance, making them a relevant host for examining genes like ARFGEF2 in colorectal pathology.
ARFGEF2 (BIG2) is a guanine nucleotide exchange factor that activates ARF GTPases, primarily ARF1 and ARF3, through GDP/GTP exchange. This activation promotes COPI coatomer assembly on Golgi membranes, facilitating retrograde transport. Upstream regulators include protein kinase A and phosphoinositides, while ARF1-GDP serves as a substrate. ARFGEF2 interacts with ARF1, GM130, dynein, and myosin IIA, and its activity drives downstream effects on clathrin adaptors and actin remodeling, integrating Golgi dynamics with cytoskeletal organization. ARFGEF2-mediated ARF activation is central to maintaining Golgi integrity and enabling efficient trafficking between the Golgi and endoplasmic reticulum.
In HT29 cells, ARFGEF2 loss is predicted to disrupt Golgi structure and vesicle trafficking, potentially impairing cell polarity, migration, and proliferation. These alterations may also influence drug sensitivity, as trafficking pathways impact receptor localization and cell signaling. Given ARFGEF2’s link to periventricular nodular heterotopia, this knockout may offer insights into the role of membrane trafficking in disease. The polyclonal format captures a range of phenotypic effects, advantageous for heterogeneous tumor modeling and functional genomics.
Research applications include dissecting ARF/COPI-mediated transport, evaluating colorectal cancer mechanisms, and testing drug responses in the context of trafficking defects. Common assays are western blotting for ARFGEF2 and GM130 to assess knockdown and pathway activation, immunofluorescence for Golgi morphology, proliferation and migration assays, and RT-qPCR for ARF1 targets. This model supports both fundamental cell biology and translational oncology investigations, enabling the study of Golgi-dependent processes in a disease-relevant background. For additional information, please contact Ascent Research.
